If Chemotherapy Is Dressed as the Grim Reaper, What Costume Does Ivermectin Wear?
by Dr. Jenn Ron
1. Welcome to the Oncology Halloween Party! Chemotherapy and Ivermectin: How We Perceive Risk
Imagine an oncology-themed Halloween party.
Platinum-based chemotherapy arrives dressed as the Grim Reaper, carrying a long list of possible adverse effects: neuropathy, bone marrow suppression, kidney injury, hearing loss, and potentially life-threatening complications.
Ivermectin arrives dressed as a slightly creepy baby, carrying decades of experience treating parasitic infections and a growing collection of laboratory studies investigating its anticancer potential.
Yet somehow, ivermectin has become the party's boogeyman.
Why do we view some medical risks as acceptable and others as frightening?
2. Behind the Costumes: Understanding Cancer Treatment Risks and Benefits
Conventional chemotherapies can cause serious and sometimes permanent adverse effects. These include neurotoxicity, organ damage, hematologic complications, and, in rare circumstances, death.
We accept these risks when clinical evidence demonstrates meaningful benefits that justify them. Chemotherapy has saved and extended countless lives.
Ivermectin, meanwhile, has a generally favorable safety profile when used at approved antiparasitic doses. Serious adverse reactions are rare yet possible, including neurological and hepatic toxicity, and its safety during prolonged or repeated cancer-directed use remains uncertain.
But here's the question: Shouldn't we evaluate every therapeutic option by examining both its potential benefits and its actual risks?
3. What Does the Ivermectin Cancer Research Actually Show?
Ivermectin is an FDA-approved antiparasitic medication that has attracted scientific interest in potential anticancer properties.
Published laboratory and animal studies have investigated several mechanisms:
PAK1 signaling: Ivermectin may interfere with pathways involved in cancer-cell growth and survival.
Apoptosis: Experimental research suggests ivermectin may promote programmed cell death in certain cancer models.
Tumor immune environment: Researchers have investigated whether ivermectin can influence immune activity and potentially enhance responses to checkpoint inhibitors.
Drug repurposing: Investigating existing medications may offer opportunities to identify new therapeutic applications without starting drug development from scratch.
These findings are intriguing, but the distinction is important: Most of this research is preclinical. We do not yet have convincing human clinical evidence demonstrating that ivermectin improves cancer survival, prevents recurrence, or slows progression.
That is a reason to pursue better research, yet who will fund this research?
4. Enter ASCO, Dressed as the Scaredy-Cat. ASCO's Guidance on Ivermectin and Cancer Treatment
And then there's ASCO, arriving at the Halloween party dressed as a scaredy-cat, looking suspiciously at ivermectin.
In June 2026, the American Society of Clinical Oncology cautioned against using ivermectin or fenbendazole for cancer treatment, including as adjunctive therapies, outside clinical trials.
I agree that patients deserve accurate information about risks, benefits, and the limitations of available research. But I also wonder whether ivermectin has become something of a scapegoat in a larger conversation about integrative oncology, naturopathic approaches, and off-label medications.
When does appropriate scientific caution become a reluctance to explore possibilities?
There is a meaningful difference between saying “We don't yet have sufficient clinical evidence” and saying “There is nothing here worth investigating.”
The first is sound scientific reasoning. The second risks closing the door on scientific curiosity.
And isn't curiosity one of the very things that advances medicine?
5. Take Off the Masks: What Should Patients Know About Repurposed Medications?
When the costumes come off, a few important truths remain.
Ivermectin is not an established cancer treatment. Its potential anticancer benefits remain investigational.
Laboratory findings are not the same as clinical outcomes. Promising mechanisms must be tested in well-designed human trials.
Safety matters. A favorable safety record in treating parasitic infections does not automatically establish safety with prolonged oncology use.
Conventional cancer therapies have demonstrated benefits. Their risks must be considered alongside the evidence supporting their use.
Open communication matters. Patients should feel comfortable discussing supplements, off-label medications, and integrative strategies with their oncology teams.
6. The Real Monster Might Be Polarization. Why Open Conversations Matter in Integrative Cancer Care
Perhaps the most frightening thing at our Halloween party isn't chemotherapy or ivermectin.
Perhaps it's a medical culture in which curiosity becomes controversy, questions become accusations, and patients become afraid to discuss what they're taking.
At MedLogic Integrative Cancer Care, I believe in examining the science, acknowledging uncertainty, respecting patient autonomy, and maintaining open communication.
The goal isn't to choose a costume. It's to see what's underneath it.
Schedule a complimentary discover call with Dr. Jenn Ron to discuss cancer care options and opportunities.
Selected Scientific References
Ivermectin, a potential anticancer drug derived from an antiparasitic drug. Pharmacological Research, 2020. https://pmc.ncbi.nlm.nih.gov/articles/PMC7505114/
Ivermectin suppresses tumour growth and metastasis through degradation of PAK1 in esophageal squamous cell carcinoma. Journal of Cellular and Molecular Medicine, 2020.
The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug. American Journal of Cancer Research, 2018.
https://pmc.ncbi.nlm.nih.gov/articles/PMC5835698/
Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer. npj Breast Cancer, 2021.
https://www.nature.com/articles/s41523-021-00229-5
Note: This article received an editorial expression of concern in 2026.
Integrated analysis reveals FOXA1 and Ku70/Ku80 as targets of ivermectin in prostate cancer. Cell Death & Disease, 2022.
Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug.
American Society of Clinical Oncology. Oncologists Urged to Take Proactive Approach When Discussing Ivermectin, Fenbendazole. June 17, 2026.
FDA. Ivermectin Prescribing Information.
Comments